News & Publications

Home Page
Realizing the promise of glycobiology

News and Publications

Here's a variety of information related to Zacharon and our research and development programs.
Should additional information be helpful, please contact us at [email protected].

News Articles and Press Releases

April 2012
Zacharon Pharmaceuticals Enters Into Agreement with Acorda Therapeutics to Develop Small Molecules Targeting Spinal Cord Injury
pdfPDF download

July 2011
Zacharon Pharmaceuticals and ARUP Laboratories Establish Partnership to Commercialize the Sensi-Pro™ Assay for Lysosomal Storage Diseases.
pdfPDF download

April 2011
Zacharon Announces Collaboration with Pfizer to Develop Drugs for Multiple Rare Diseases
pdfPDF download

January 2011
Zacharon and Mayo Clinic Enter Collaboration to Develop Clinical Diagnostics Based on Zacharon's Breakthrough Assay Technology
pdfPDF download

November 2010
Zacharon Presents Preclinical Data on Lead Cancer Programs at the National Cancer Institute Investor Forum.

November 2010
Zacharon Awarded Nearly $1 Million in Grant Funding Through the Qualifying Therapeutic Discovery Project Tax Grant Program.

June 2010
Zacharon Presents Key Data on Lead Therapeutic Program at the 11th International Symposium in Mucopolysaccharide & Related Diseases.

December 2009
Zacharon Pharmaceuticals Emerging Company Profile published in

December 2008
Zacharon Pharmaceuticals Targets Glycans with Small Molecules (BioWorld)
pdfPDF download

November 2008
Zacharon Pharmaceuticals Completes $3.5 Million Series A Financing and Receives More Than $2.2 Million in NIH Grants
pdfPDF download

Scientific Publications and Papers

Xiaomei Bai, et. al., Novel Approach for Treating Neural Crest Derived Tumors: Selective Inhibition of Ganglioside Biosynthesis With Small Molecules. AACR 102nd Annual Meeting 2011.
pdfPDF download

Ganglioside Inhibitor Program White Paper
pdfPDF download

Mucopolysaccharidosis I, II, and III Program White Paper
pdfPDF download

Brown JR, et. al., Small Molecule Inhibitors of Glycosaminoglycan Biosynthesis as a Substrate Optimization Therapy for the Mucopolysaccharidoses. Lysosomal Disease Network WORLD Symposium 2011.
pdfPDF download

Xiaomei Bai, et. al., Small Molecule Inhibitors of Ganglioside Biosynthesis as a Substrate Reduction Therapy for the Gangliosidoses. Lysosomal Disease Network WORLD Symposium 2011.
pdfPDF download

Brown JR,, Glycan-Based Biomarkers for Lysosomal Storage Disease: The Sensi-Pro Assay.
Lysosomal Disease Network WORLD Symposium 2010.
pdfPDF download

Brown JR, Crawford BE, Esko JD.
Glycan Antagonists and Inhibitors: a Fount for Drug Discovery.
Crit Rev Biochem Mol Biol 2007; 42(6), 481-515. PMID: 18066955

Brown JR, Fuster MM, Li R, Varki N, Glass CA, Esko JD. 2006.
A Disaccharide-Based Inhibitor of Glycosylation Attenuates Metastatic Tumor Cell Dissemination.
Clin Cancer Res 2006; 12(9), 2894-901. PMID: 16675586

Brown JR, Fuster MM, Whisenant T, Esko JD.
Expression Patterns of ?2,3-Sialyltransferases and ?1,3-Fucosylatransferases Determine the Mode of Sialyl Lewis X Inhibition by Disaccharide Decoys.
J Biol Chem 2003; 278 (26), 23352-23359. PMID: 12686549